Skip to main content

Table 2 Per-cancer characteristics of low- and high-risk patients

From: The impact of pharmacokinetic gene profiles across human cancers

  Low-risk cohort High-risk cohort
N Age Stage 1 or 2 Stage 3 or 4 Grade 1 or 2 Grade 3 or 4 N Age Stage 1 or 2 Stage 3 or 4 Grade 1 or 2 Grade 3 or 4
Any-Hit Model
 GBM 125 62 ± 13.3 9 52 ± 23.7
 BRCA 697 59 ± 13.3 533 164 118 53 ± 13.3 96 22
 OV 159 58 ± 10.4 9 150 17 142 103 57 ± 13.3 10 93 19 84
 KIRC 456 61 ± 13.3 389 67 211 245 14 58.5 ± 11.1 2 12 1 13
 LUAD 319 67 ± 10.4 246 73 10 62.5 ± 12.6 6 4
 UCEC 289 63 ± 10.4 226 63 164 125 44 61.5 ± 9.6 13 31 12 32
 HNSC 287 61 ± 11.9 136 151 199 78 16 56.5 ± 10.4 14 2 11 5
 LUSC 198 68.5 ± 8.2 152 46 14 65.5 ± 8.9 12 2
Therapy Efficacy Model
 GBM 127 61 ± 13.3 7 52 ± 23.7
 BRCA 776 58 ± 13.3 602 174 0 0 39 53 ± 13.3 27 12
 OV 228 58 ± 11.1 16 212 31 197 34 60.5 ± 11.9 3 31 5 29
 KIRC 463 61 ± 13.3 390 73 212 251 7 54 ± 8.9 1 6 0 7
 LUAD 321 67 ± 10.4 247 74 0 0 8 67 ± 10.4 5 3
 UCEC 310 63 ± 10.4 231 79 168 142 23 61 ± 10.4 8 15 8 15
 HNSC 288 61 ± 11.9 137 151 200 78 15 57 ± 13.3 13 2 10 5
 LUSC 202 68.5 ± 8.2 155 47 0 0 10 65 ± 8.9 9 1